[
  {
    "names": ["AMG529"],
    "company": "Amgen",
    "genes": ["ASGR1"],
    "clinical_annotation": ["NA"],
    "pathway_annotation": ["NA"],
    "diseases": ["Cardiovascular Disease"],
    "targets": [
      {
        "names": ["asialoglycoprotein receptor 1"]
      }
    ],
    "mechanism_of_action": ["asialoglycoprotein receptor 1 inhibitor"],
    "indications": ["Cardiovascular Disease"],
    "indication_type": "Cardiovascular",
    "year_discontinued": 2019,
    "phase": 1,
    "discontinuation_reason": "commercialization related",
    "link": "https://www.evaluate.com/vantage/articles/events/conferences/jp-morgan-2019-day-two-roundup-after-party-harsh-reality",
    "repurposed_efforts": ["NA"],
    "repurposed_drug_name": "NA",
    "repurposed_indications": ["NA"],
    "repurposed_year": null,
    "repurposed_company": null,
    "repurposed_phase": null
  },
  {
    "names": ["LY3463251"],
    "company": "Eli Lilly",
    "genes": ["GDF15"],
    "clinical_annotation": ["NA"],
    "pathway_annotation": ["NA"],
    "diseases": ["Type 2 Diabetes", "Obesity"],
    "targets": [
      {
        "names": ["growth differentiation factor 15"]
      }
    ],
    "mechanism_of_action": ["growth differentiation factor 15 agonist"],
    "indications": ["Type 2 Diabetes/Obesity"],
    "indication_type": "Metabolic",
    "year_discontinued": 2020,
    "phase": 1,
    "discontinuation_reason": "NA",
    "link": "https://investor.lilly.com/static-files/e84b2d25-8e5b-4041-b7f0-8a1749fb9f77",
    "repurposed_efforts": ["NA"],
    "repurposed_drug_name": "NA",
    "repurposed_indications": ["NA"],
    "repurposed_year": null,
    "repurposed_company": null,
    "repurposed_phase": null
  },
  {
    "names": ["LY3325656"],
    "company": "Eli Lilly",
    "genes": ["GPR142"],
    "clinical_annotation": ["NA"],
    "pathway_annotation": ["NA"],
    "targets": [
      {
        "names": ["G protein-coupled receptor 142"]
      }
    ],
    "mechanism_of_action": ["G protein-coupled receptor 142 agonist"],
    "indications": ["Type 2 Diabetes"],
    "indication_type": "Metabolic",
    "year_discontinued": 2018,
    "phase": 1,
    "discontinuation_reason": "NA",
    "link": "https://investor.lilly.com/static-files/3556875d-ae48-4911-99ba-05647b225ed5",
    "repurposed_efforts": ["Diabetic retinopathy", "Pain"],
    "repurposed_drug_name": "NA",
    "repurposed_indications": ["NA"],
    "repurposed_year": null,
    "repurposed_company": null,
    "repurposed_phase": null
  },
  {
    "names": ["KBP-089", "DACRA-089"],
    "company": "Eli Lilly",
    "genes": ["IAPP/CALCR"],
    "clinical_annotation": ["rocuronium dosage"],
    "pathway_annotation": ["NA"],
    "targets": [
      {
        "names": ["amylin/calcitonin receptor"]
      }
    ],
    "mechanism_of_action": ["amylin", "calcitonin receptor dual agonist"],
    "indications": ["Type 2 Diabetes"],
    "indication_type": "Metabolic",
    "year_discontinued": null,
    "phase": 1,
    "discontinuation_reason": "NA",
    "link": "https://investor.lilly.com/static-files/68230d7a-ba20-43dc-979b-fea529a5e6c4",
    "repurposed_efforts": ["NA"],
    "repurposed_drug_name": "NA",
    "repurposed_indications": ["NA"],
    "repurposed_year": null,
    "repurposed_company": null,
    "repurposed_phase": null
  }
]
